Depressive Disorders - Europe

  • Europe
  • Revenue in the Depressive Disorders market is projected to reach US$6.39bn in 2024.
  • Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 1.19%, resulting in a market volume of US$6.70bn by 2028.
  • In global comparison, most revenue will be generated in the United States (US$6,263.00m in 2024).
  • In relation to total population figures, per person revenues of US$158.00 are generated in 2024.

Key regions: Japan, United Kingdom, China, Europe, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Depressive Disorders market in Europe is experiencing significant growth and development due to various factors.

Customer preferences:
Customers in Europe are increasingly seeking effective and accessible treatments for depressive disorders. There is a growing demand for medications that can effectively alleviate symptoms of depression and improve overall well-being. Customers are also showing a preference for non-pharmacological treatments, such as therapy and counseling, as they are seen as more holistic and less reliant on medication.

Trends in the market:
One of the key trends in the Depressive Disorders market in Europe is the increasing use of digital health solutions. Mobile applications and online platforms are being developed to provide mental health support and therapy to individuals suffering from depression. These digital solutions offer convenience and accessibility, allowing individuals to seek help and support from the comfort of their own homes.Another trend in the market is the focus on personalized medicine. Researchers and pharmaceutical companies are investing in the development of targeted therapies that can address the specific needs of individuals with depressive disorders. This personalized approach aims to improve treatment outcomes and minimize side effects.

Local special circumstances:
Each country in Europe has its own unique healthcare system and regulations, which can impact the availability and accessibility of treatments for depressive disorders. Some countries may have a more comprehensive mental health support system, while others may have limited resources. These local special circumstances can influence the adoption and utilization of different treatment options.

Underlying macroeconomic factors:
The growing awareness and understanding of mental health issues, including depressive disorders, have led to increased investments in the healthcare sector. Governments and healthcare providers are allocating more resources to mental health services, including the treatment of depressive disorders. This increased funding is driving innovation and the development of new treatment options.Additionally, the aging population in Europe is contributing to the growth of the Depressive Disorders market. Older individuals are more susceptible to depressive disorders, and as the population ages, the demand for effective treatments is expected to rise. This demographic shift is creating opportunities for pharmaceutical companies and healthcare providers to cater to the specific needs of this population segment.In conclusion, the Depressive Disorders market in Europe is evolving and expanding due to customer preferences for effective and accessible treatments, the adoption of digital health solutions, the focus on personalized medicine, local special circumstances, and underlying macroeconomic factors such as increased investments in mental health services and the aging population.

Methodology

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

Overview

  • Revenue
  • Patients
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)